Rxbio, Inc.
- UEI
- DB9LSMAHKNJ8
- CAGE
- 4CJP9
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeted therapies for the treatment of GI-ARS diarrhea | National Institute of Diabetes and Digestive and Kidney Diseases | $252,128 | |
| IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. | National Institute of Allergy and Infectious Diseases | $4,591,512 | |
| The anti-diarrheal potential of a LPA analog RX100 | National Institutes of Health | $222,829 | |
| Development of RX100 as novel medical countermeasure for acute radiation syndrome | National Institutes of Health | $297,087 | |
| Non toxic insect resistant textiles for military clothing | Department of Defense | $734,075 |
Quick answers
What is Rxbio, Inc.'s UEI?
Rxbio, Inc.'s Unique Entity ID (UEI) in SAM.gov is DB9LSMAHKNJ8.
What is Rxbio, Inc.'s CAGE code?
Rxbio, Inc.'s CAGE code is 4CJP9.
What is Rxbio, Inc.'s primary NAICS code?
Rxbio, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Rxbio, Inc. registered in SAM.gov?
Rxbio, Inc.'s SAM.gov registration expired on April 3, 2024.
What is Rxbio, Inc.'s most recent federal award?
Rxbio, Inc.'s most recent federal grant award is Targeted therapies for the treatment of GI-ARS diarrhea (R41DK125208), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 18, 2020.
On GovTribe
See Rxbio, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors